Industry analyst GlobalData has outlined the driving factors in hematology, identifying Ultomiris (ravulizumab), Hemlibra (emicizumab) and Vafseo (vadadustat) a 22 May 2023
Californian biopharmaceutical firm Amgen as reported a 2% drop in revenues in the first quarter, to $6.1 billion, a reflection of falling sales of COVID-19 ther 28 April 2023
Gilead Sciences subsidiary company Kite has announced the publication of a new European analysis of commercial manufacturing experience of Yescarta (axicabtagen 24 April 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.